LIVINGSTON, N.J. and MELVILLE, N.Y., Jan. 16 /PRNewswire-FirstCall/ -- Milestone Scientific, Inc. , the recognized leader in advanced injection technologies and Henry Schein, Inc. , the largest provider of healthcare products and services to office-based practitioners in the combined North American and European markets, today announced that the companies have signed a distribution agreement granting Henry Schein exclusive distribution rights to market Milestone’s Single Tooth Anesthesia (STA(TM)) system and other products to dental professionals in the United States and Canada.
Milestone’s STA system is designed to allow dentists to immediately administer the periodontal ligament injection, to anesthetize a single tooth, without first administering a mandibular block that anesthetizes an entire quadrant of the jaw. The periodontal ligament injection is highly valued among dentists and the Milestone system allows it to be more efficiently administered, while avoiding collateral numbing of the cheek, lips and jaw. The STA system uses Milestone’s patented CompuFlo(TM) pressure sensing technology to provide the dentist with valuable information on the pressures created in the tissue being injected. The patented CompuFlo technology is believed to have broad applications in medicine and dentistry and STA system is the first commercial application using this advanced real time pressure sensing technology.
“At Sullivan-Schein Dental, we are committed to offering our customers technologically advanced exclusive products to enhance the practice of dentistry, and Milestone’s STA system is an important addition to that roster,” said Tim Sullivan, President of Sullivan-Schein Dental, Henry Schein’s U.S. Dental division. “We are very pleased to be teaming with Milestone to make the STA system available to our dental customers in the United States and Canada.”
Leonard Osser, Milestone’s Chairman and CEO, added, “The development of our STA system is the culmination of many years work to develop a more dentist friendly and more efficient system for painlessly anesthetizing a single tooth. We believe that the STA system should set a new standard of patient care and are pleased that the world’s leading dental distribution company shares our vision.”
About Henry Schein
Henry Schein, a Fortune 500(R) company, is recognized for its excellent customer service and highly competitive prices. The Company’s four business groups -- Dental, Medical, International and Technology -- serve more than 500,000 customers worldwide, including dental practices and laboratories, physician practices and veterinary clinics, as well as government and other institutions. The Company operates through a centralized and automated distribution network, which provides customers in more than 200 countries with a comprehensive selection of more than 70,000 national and Henry Schein private-brand products in stock, as well as over 100,000 additional products available to our customers as special order items. Henry Schein also offers a wide range of innovative value-added practice solutions for healthcare professionals, such as ArubA(R), the Company’s electronic catalog and ordering system. Its leading practice-management software solutions have been installed in more than 50,000 practices, including DENTRIX(R) and Easy Dental(R) for dental practices, and AVImark(R) for veterinary clinics. Headquartered in Melville, N.Y., Henry Schein employs more than 11,000 people and has operations in 19 countries. The Company’s sales reached a record $4.6 billion in 2005. For more information, visit the Henry Schein Web site at www.henryschein.com.
About Milestone Scientific, Inc.
Headquartered in Livingston, New Jersey, Milestone Scientific is engaged in pioneering proprietary, highly innovative technological solutions for the medical and dental markets. Central to the Company’s IP platform and product development strategy is its patented CompuFlo(TM) technology for the improved and painless delivery of local anesthetic. Specifically, CompuFlo is a computer-controlled, pressure sensitive infusion, perfusion, suffusion and aspiration technology, which provides real-time readouts of pressures, fluid densities and flow rates, enabling the advanced delivery and removal of a wide array of fluids. The Single Tooth Anesthesia (STA(TM)) computer-controlled local anesthesia delivery system which uses this technology provides dentists with audible and visual signals as to in-tissue pressure. Milestone’s existing painless injection systems are currently sold in 25 countries. For more information on these and other innovative Milestone products, please visit the Company’s web site found at www.milesci.com.
Milestone Scientific, Inc. Safe Harbor Statement: This press release contains forward-looking statements regarding the timing and financial impact of the Milestone’s ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone’s control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone’s periodic filings with the Securities and Exchange Commission, including without limitation, Milestone’s Annual Report on Form 10-KSB for the year ended December 31, 2006. The forward looking- statements in this press release are based upon management’s reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Henry Schein, Inc. Safe Harbor Statement: In accordance with the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors which, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements, or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are identified by the use of such terms as “may,” “could,” “expect,” “intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate” or other comparable terms. A full discussion of our operations and financial condition, including factors that may affect our business and future prospects, is contained in documents we have filed with the SEC and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.
Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: competitive factors; changes in the healthcare industry; changes in government regulations that affect us; financial risks associated with our international operations; fluctuations in quarterly earnings; our dependence on third parties for the manufacture and supply of our products; transitional challenges associated with acquisitions; regulatory and litigation risks; the dependence on our continued product development, technical support and successful marketing in the technology segment; our dependence upon sales personnel and key customers; our dependence on our senior management; possible increases in the cost of shipping our products or other service trouble with our third-party shippers; risks from rapid technological change; risks from potential increases in variable interest rates; financial risks associated with acquisitions; possible volatility of the market price of our common stock; certain provisions in our governing documents that may discourage third-party acquisitions of us; and changes in tax legislation that affect us. The order in which these factors appear should not be construed to indicate their relative importance or priority.
We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, forward- looking statements should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward- looking statements.
FOR: Henry Schein, Inc. CONTACT: Susan Vassallo Director, Corporate Communications susan.vassallo@henryschein.com (631) 843-5562 FOR: Milestone Scientific, Inc. CONTACT: Elite Financial Communications Group, LLC Dodi Handy, President and CEO, or Daniel Conway, Chief Strategist 407-585-1080 or mlss@efcg.net
Milestone Scientific, Inc.
CONTACT: Susan Vassallo, Director, Corporate Communications of HenrySchein, Inc., +1-631-843-5562, susan.vassallo@henryschein.com; or DodiHandy, President and CEO, or Daniel Conway, Chief Strategist, both of EliteFinancial Communications Group, LLC, +1-407-585-1080, mlss@efcg.net, forMilestone Scientific, Inc.
